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Abstract
Somatic sensations induced by placebos are a frequent phenomenon whose etiology and
clinical relevance remains unknown. In this study, we have evaluated the quantitative, quali-
tative, spatial, and temporal characteristics of placebo-induced somatic sensations in re-
sponse to three different placebo interventions: (1) placebo irritant solution, (2) placebo
laser stimulation, and (3) imagined laser stimulation. The quality and intensity of evoked
sensations were assessed using the McGill pain questionnaire and visual analogue scales
(VAS), while subjects’ sensation drawings processed by a geographic information system
(GIS) were used to measure their spatial characteristics. We found that all three interven-
tions are capable of producing robust sensations most frequently described as “tingling”
and “warm” that can reach consider-able spatial extent ( 205mm²) and intensity ( 80/100
VAS). Sensations from placebo stimulation were often referred to areas remote from the
stimulation site and exhibit considerable similarity with referred pain. Interestingly, there
was considerable similarity of qualitative features as well as spatial patterns across subjects
and placebos. However, placebo laser stimulation elicited significantly stronger and more
widespread sensations than placebo irritant solution. Finally, novelty seeking, a character
trait assessed by the Temperament and Character Inventory and associated with basal do-
paminergic activity, was less pronounced in subjects susceptible to report placebo-induced
sensations. Our study has shown that placebo-induced sensations are frequent and can
reach considerable intensity and extent. As multiple somatosensory subsystems are in-
volved despite the lack of peripheral stimulus, we propose a central etiology for this
phenomenon.
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Introduction
Placebo effects have established their veracity both in clinical trials and experimental studies
[1]. Recent studies have also delineated a neurobiological substrate for placebo effects [2,3].
Moreover, several psychological constructs have been posited to explain placebo effects, such
as verbal expectations, classical conditioning, anxiety reduction and social observation [4,5].
There is also a long history of experiments providing evidence that different placebo treatments
such as dummy devices, sham surgery and placebo pills produce different clinical outcomes
[6–13].
While previous studies have predominantly seen placebos as a form of therapeutic interven-
tion (cf. Shapiro’s definition from 1968 [14]), here we study sham procedures similar to those
commonly used in placebo studies (lasers, topical medication) without explicitly referring to
any therapeutic potential. Using this broader definition of placebos, we study a little-researched
phenomenon that may complement current views, namely somatic sensations induced by pla-
cebo interventions. Although they are frequently reported in the literature, little is known
about their etiology.
Interventions reported to elicit sensations include placebo injections [15], placebo transcu-
taneous electrical nerve stimulation [16], placebo acupuncture [17,18], and placebo laser stim-
ulation [19,20]. While the first two studies only reported that sensations were elicited, the latter
four explored them in some detail, focusing on incidence [17,18], descriptor frequency, and in-
tensity [19,20]. To our knowledge, no study has explored spatial and temporal characteristics
of placebo-induced sensations. Furthermore, all previous studies investigating placebo-induced
sensations compared active exposure (e.g. acupuncture) versus placebo exposure as a primary
question, which may have led to specific expectations in subjects and, hence, influenced the
outcome. Therefore, we designed our study to avoid any reference to placebos or any therapeu-
tic interventions.
We conducted three experiments. In Experiments 1 and 2, placebos with different tactile
components were tested for the somatic sensations they evoke. We hypothesized that placebo-
induced sensations are a phenomenon that can be triggered by a variety of different placebos,
and that a common etiology underlies these sensation reports. Therefore, we expected quanti-
tative (e.g. intensity and extent) but not qualitative differences (e.g. descriptor profiles) between
the different tested placebos. In Experiment 3, we aimed at minimizing possible influences
from the experimenter or laboratory setting by replacing “actual” placebo stimulation with
laser stimulation that was only imagined by subjects at home.
Placebo-induced sensations were studied using the McGill questionnaire [21] and visual an-
alogue scales. Spatial characteristics were assessed by analyzing subjects’ sensation drawings on
body outlines with a geographic information system (GIS) [22]. Since a number of previous
studies have linked placebo analgesia to basal dopaminergic regulation [23], we assessed novel-
ty seeking as a character trait linked to dopamine [24] and investigated possible correlations
between novelty seeking and subjects’ susceptibility to develop placebo-induced sensations.
Finally, we compared the spatial patterns of placebo-induced sensations to that of referred
pain and to sensation patterns from our previous study using true low-level laser stimulation
[22].
Materials & Methods
Experimental design
We performed three experiments to quantify the susceptibility of healthy subjects to placebo-
induced sensations. Experiments 1 and 2 took place under laboratory conditions (room
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temperature of ~20°C controlled by AC, no disturbances by noise) and were identical in design
except for the stimulus modality. All measurements took place between 12 a.m. and 7 p.m. Ex-
periment 3 was conducted as a questionnaire study to eliminate any influence a laboratory set-
ting might have on placebo-induced sensations. Experiment 1 used a placebo with a small but
noticeable tactile component (water drenched cotton bud on the skin), Experiment 2 had no
tactile component (inactive laser held over the skin). Experiment 3 aimed at minimizing possi-
ble influences from the experimenter or laboratory setting by replacing “actual” placebo stimu-
lation with laser stimulation that was imagined by subjects at home.
Subjects
All subjects taking part in the study were healthy on the day of the measurement and did not
have scars or injuries at any of the stimulation sites. None of them had any history of neurolog-
ical disease or took any kind of medication on a regular basis other than oral contraceptives.
The intake of analgesics as rescue medication was prohibited during the five days before the
measurement. All subjects were right-handed (self-report). For Experiments 1 and 2, two
groups of 30 subjects each were included in the study. Subjects of Experiment 1 (12 male) had
a mean age (± S.D.) of 23.6 ± 3.5 years, while those of Experiment 2 (8 male) had a mean age of
24.5 ± 7.4 years. For Experiment 3, a questionnaire was sent out by mail to 104 healthy subjects
that had previously been recruited and screened for taking part in an unrelated study. 56 sub-
jects (21 male) returned a complete and valid questionnaire. All subjects were at least 18 years
old, which is the legal age in Germany. The mean age was 25.3 ± 6.6 years. All three subject co-
horts were independent and there were no differences in gender balance between them (Fish-
er’s exact test: p = 0.4118 for exp. 1 vs. 2, p = 0.8207 for exp. 1 vs. 3, and p = 0.3481 for exp. 2
vs. 3). The study was conducted according to the Declaration of Helsinki and all participants
gave written informed consent following the guidelines of the ethics committee of the Universi-
ty Hospital Jena, which had approved the study.
Stimulation loci and duration
Placebo stimulation for Experiments 1 and 2 took place at three different loci (Fig 1), each of
them being stimulated with both placebos. The first location was on the dorsal aspect of the lit-
tle finger, approximately 1 mm from the proximal ulnar corner of the nail. The second was on
the dorsal aspect of the little toe, approximately 1 mm from the proximal lateral corner of the
nail. The third was on the abdomen, approximately 3 cm lateral to the navel. Each stimulation
run had a baseline of 30 seconds followed by three minutes during which subjects were asked
to focus on their sensations. We chose this rather long period since we wanted to leave enough
time for possible processes like temporal summation to fully develop. Points were stimulated in
pseudo-randomized order that was repeated once (i.e. six runs in total) and only the left side of
the body was stimulated. All measurements were carried out by one of three different female
experimenters.
Body Outline
To assess and compare bodily sensations experienced by the subjects, we used a semi-struc-
tured approach based on subjects’ drawings over a pictorial body outline. Body outlines were
adapted from the illustrations in Head (1893) [25] (S1 Fig) and were successfully used in our
previous study [22]. A new paper copy of these body outlines was handed out to the subjects
after each stimulation run (subjects’ blindfold was removed for this). The instructions given to
the subjects in Experiments 1 and 2 were (translated to English): “Draw a point for every
point-like sensation, a line for every line-like sensation and shade in a region for every area-like
Placebo-Induced Somatic Sensations
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Fig 1. Stimulation loci and placebo interventions. a) Locations stimulated in the experiment. b) Placebos used in the study. Left side: Placebo irritant
solution (water), right side: Placebo laser (switched off). c) Application of the two placebos to the little finger of the hand.
doi:10.1371/journal.pone.0124808.g001
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sensation.” Please note that here and in the following, “point-like”, “line-like” and “area-like”
refer to the spatial and not temporal characteristics of the sensations. In Experiment 3, the
same body outlines were used, albeit with different instructions (see below).
Sensory descriptors and intensity rating
For a comprehensive list of sensory descriptors, the German version of the McGill pain ques-
tionnaire [21,26] was used. The order of its 77 descriptors (sensory, affective, and evaluative)
was randomized for each subject. Due to our experience from an earlier study [22], we added
the descriptor “warm”. In Experiments 1 and 2, subjects were asked to choose any number of
descriptors that matched their sensations and to rate the intensity of each chosen descriptor on
a 100-point visual analogue scale ranging from “not felt” (0) to “maximal tolerable intensity”
(100). They were also free to add descriptors of their own. The VAS score of the descriptor
with the highest rating was used to assess the overall intensity of the sensation. The raw data
for this and all other collected data can be found in the supporting information (S1 Raw Data).
Experiment 1
Placebo. In the first experiment, a placebo irritant solution, which consisted of ordinary
tap water at room temperature, was used and applied to the skin with a cotton bud. We in-
vented the name “Aegoloprom” as a neutral term after preliminary experiments had shown
that a placebo solution named “Capsitol”mainly induced local burning sensations as some sub-
jects suspected it to contain capsaicin.
Procedure. To reduce anxiety, subjects were told that the active ingredient of the solution
was a food additive and that stimulation with a weak concentration of this substance should
not induce significant side effects. To increase credibility, we suggested that the following side
effects may occur when the solution was applied over a longer time period: allergic reactions,
transient sensations and local reddening of the skin. Subjects were instructed not to bring any
of the substance into their eyes as this might cause local irritation. The cotton bud was
drenched in water and subsequently applied to the skin for ten seconds. Care was taken to
apply only a minimal amount of water that would not run down the body. Subjects were blind-
folded during each of the six experimental runs.
The following instructions were read aloud to the subjects (comments in italic are added for
clarity and were not part of the text): “This is a perception experiment. We are interested in the
sensations that can be elicited by stimulation with a weak solution (Experiment 1 only) / a weak
laser (Experiment 2 only). The name of the solution is Aegoloprom (sentence deleted in Experi-
ment 2). I will reveal its mechanism of action to you at the end of the experiment. Please moni-
tor sensations in your body during the whole measurement, especially at the points stimulated.
At the end of the experiment, report all sensations that you attribute to the stimulation. Draw
these sensations on the body outlines. Draw a point for every point-like sensation, a line for
every a line-like sensation and hachures for every area-like sensation. Subsequently, chose any
number of words from the list that best describe your sensation. If none of the words describe
your sensation adequately, you may also use words of your own. Finally, mark the intensity of
your sensation on this visual analogue scale. The left end of the scale stands for no sensation,
the right end for a strong sensation on the verge of intolerable. Some people have a sensation,
when they are stimulated, others do not. One is not better or worse than the other.”
After lying down on the stretcher, subjects were further instructed: “For the next few mo-
ments, please do nothing and concentrate on what you feel, e.g. how it feels like to lie on this
stretcher. Any sensations you may just have had are not those that are important when I will
later ask you what you felt.”
Placebo-Induced Somatic Sensations
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Right before the experiment started, subjects were instructed to report the onset of every
new sensation they may have to the experimenter. The onset of the first reported sensation was
measured with a stopwatch. After subjects had completed the experiment, they were asked
what they thought/believed the purpose of the study was.
Experiment 2
Placebo. In the second experiment on an independent cohort, a low-level (20mW) laser
device, emitting red light (Laserneedle micro, Laserneedle EG GmbH, Wehrden, Germany)
was used as the placebo. During the stimulation phase, the optode at the end of the fiber optical
cable of the laser was held over the point that was stimulated without touching the skin or skin
hair. The laser, however, was switched off during the whole procedure. Subjects were blind-
folded during each of the six experimental runs.
Procedure. Before the experiment started, the laser was switched on and the red laser light
was briefly shone on the subjects’ right hand to reduce their anxiety. The instructions given to
the subject were the same as in Experiment 1. The side effect “allergic reaction” was replaced
by “possible damage to the eyes, when directly exposed to the laser light”. Again, the onset of
the first reported sensation was measured with a stopwatch and after completing the experi-
ment, subjects were asked for what they thought was the purpose of the study.
Experiment 3
Imagined stimulation. In the third experiment run on an independent cohort of subjects,
no actual placebo was used. Instead, we asked subjects to imagine being stimulated with a red
laser and to draw the sensations that may result from this stimulation. As we aimed at eliminat-
ing any laboratory context and influence of the experimenter, we used a questionnaire that was
sent out to subjects by mail and filled out at home.
Procedure. The questionnaire was based on the same body outlines used in Experiments 1
and 2 and contained 8 pages (only front and back views of the body). On each page, the stimu-
lation locus to be imagined was marked with a red dot. Stimulation loci were taken from a pre-
vious study [22], where subjects had also reported sensations during placebo stimulation that
were predominantly line-like in shape. We only report results from the little finger and toe
here, as those locations were also stimulated in Experiments 1 and 2.
The questionnaire came with the following instructions: “On the following pages you will
find body outlines. Each outline contains a red dot (S2 Fig). Please imagine your own body
being stimulated with weak red laser light at the marked position. The laser light is shone di-
rectly onto your skin using a fiber optical cable. The laser stimulation shall last for some min-
utes and elicits a line-like sensation. How you imagine this sensation is the object of this
study.”
Subjects then received instructions on how to draw their imagined sensations: “On every
page you will find a green arrow next to the body outline. This arrow represents the line-like
sensation. Please draw a line into the body outline that has approximately the same length and
that best describes your imagined sensations. The line does not have to be straight and may fol-
low any course but is not allowed to intersect with itself. Please make sure that the line does not
leave the borders of the body outline.”
On its last page, the questionnaire contained six items in the form of self-referential state-
ments that subjects could rate on a five point scale (from “strongly disagree” to “strongly
agree”). The central statement was “I had actual sensations at the marked locations.” The other
five items were added to distract the subject from the true object of the study. Subjects that an-
swered with “agree” or “strongly agree” were then asked to describe their sensations using their
Placebo-Induced Somatic Sensations
PLOS ONE | DOI:10.1371/journal.pone.0124808 April 22, 2015 6 / 21
own words. These subjects are called “susceptible” in the rest of the manuscript, all others
“non-susceptible”.
Assessment of character traits. To assess whether the susceptibility for placebo-induced
sensation under imagined stimulation was associated with certain character traits, all subjects
that took part in Experiment 3 also filled out the Temperament and Character Inventory, TCI
[27] in its German version 9 (240 items, true/false scoring). The TCI operates with four tem-
peraments (novelty seeking, harm avoidance, reward dependence, persistence) and three char-
acter traits (self-directedness, cooperativeness, self-transcendence) as personality traits. It is
based on a psychobiological model that attributes high scores in novelty seeking, harm avoid-
ance, and reward dependence, to low basal dopaminergic activity, high serotonergic activity,
and low basal noradrenergic activity, respectively [24]. Validity of these attributions has been
shown using positron emission tomography [28] as well genetic polymorphisms [29].
Data analysis
Frequency of placebo-induced sensations. To assess a possible interrelation between the
placebo type and the overall number of trials that elicited sensations, a two-tailed Fisher’s exact
test was used. Possible associations between the different stimulation sites and sensation fre-
quencies were also assessed using a two-tailed Chi-squared test for the pooled data of Experi-
ments 1 and 2. Here and in all following tests (unless stated otherwise), a p-value below 0.05
was considered significant.
Intensity of placebo-induced sensations. Two-sided two-sample t-tests were calculated
to compare placebo irritant solution sensation intensity vs. placebo laser sensation intensity for
all three stimulation sites.
Geometric features of placebo-induced sensations. Following a previously validated ap-
proach [22] sensation drawings were analyzed using a geographic information system (GIS,
[30]). To compare the localization and extent of the sensations drawn by subjects from differ-
ent study groups, the body outline was digitized and scaled to a body height of 175cm to use
within the GIS body-map template in ArcGIS 10.0 (esri GmbH, Kranzberg, Germany). All
body sketches were scanned, transferred into the GIS database, and geo-referenced to the
body-map template. The database was then populated with the subjects’mapped sensations in
point, polyline, and polygon format by manually digitizing them on-screen from the scanned
sketches.
For sensations of line-like and two-dimensional shape, the line length and polygon area
were calculated. Possible differences in the overall length or area between placebos were as-
sessed using two-sided two-sample t-tests of the data pooled from all stimulation sites and
repetitions.
For illustration purposes, lines were converted to 1.5 cm wide swaths of polygons by a buff-
ering algorithm to overlay multiple line-like and/or two-dimensional sensations in a single
plot. Finally, all sensations were overlaid and thresholded to display only areas that had been
drawn by at least two different subjects.
Comparison of sensation patterns evoked by placebo laser versus referred pain. To ex-
plore possible parallels between the observed referral of placebo-induced sensations and the
phenomenon of referred pain, we compared the spatial patterns from Experiments 2 and 3 to
that of referred pain from the literature. As a reference, we chose[31]. This group used hyper-
tonic saline injections into paravertebral muscles at different segments to elicit referred pain.
As we had observed similar patterns in a previous study using low-level laser stimulation [22],
we also included these patterns in the comparison.
Placebo-Induced Somatic Sensations
PLOS ONE | DOI:10.1371/journal.pone.0124808 April 22, 2015 7 / 21
Verbal descriptors of placebo-induced sensations. The average number of descriptors in
Experiment 1 and 2 that were chosen by susceptible subjects to rate their sensations was calcu-
lated by averaging over all stimulation sites and repetitions. Wilcoxon’s signed-rank test was
used to test for differences between the experiments as well as between different points. For the
latter, data from Experiments 1 and 2 were pooled. For each descriptor, we calculated the per-
centage of subjects that chose it. Descriptors that were chosen several times by the same subject
were only counted once. For the most common descriptors, mean VAS scores were calculated.
For the same descriptors Mann-Whitney tests were used to detect possible differences between
placebo types. P-values were Bonferroni corrected for multiple comparisons.
Onset of placebo-induced sensations. The onset of a sensation was defined as the time
between the beginning of stimulation (i.e. the moment, when the cotton bud was placed on the
skin or subjects were told that the laser was switched on) and the moment, when the first sensa-
tion was verbally reported by the subject. It was measured by the experimenter with a stop
watch. To increase power, data were pooled for all stimulation sites and repetitions. Differences
between the two placebos were assessed using a Kolmogorov-Smirnov test, as the data were not
normally distributed (Anderson-Darling test: p<0.05).
Influence of character traits. T-values were calculated from the raw TCI results based on
the instructions in the questionnaire’s manual. A one-sided two-sample t-test was used to test
the hypothesis of lower novelty seeking values in subjects susceptible to placebo-induced sensa-
tions. Additional two-sided two-sample t-tests were calculated for the other three tempera-
ments “harm avoidance”, “reward dependence”, and “persistence”. A multiple comparisons
corrected p-value of 0.0167 or lower (0.05 corrected for 3 comparisons) was considered
significant.
Results
Susceptibility to placebo-induced sensation and drop-outs
Subjects that reported any sensations during one of the experimental runs after filling out the
questionnaire are henceforth called susceptible, all others non-susceptible.
The percentage of susceptible subjects was 90.0%, 86.7% and 27.6% for Experiments 1, 2
and 3, respectively. One subject dropped out during a stimulation run in Experiment 2, because
the sensation became unbearably strong. She later resumed the experiment.
Frequency of placebo-induced sensations
The frequency of sensations for the different placebos and stimulation sites were as follows.
Subjects reported sensations during 124 of the 180 stimulation trials (30 subjects x 3 points x 2
runs) for placebo irritant solution and during 106 of the 180 trials for placebo laser. There was
a trending significant association between placebo type and sensation frequency (p = 0.062),
i.e. a trend for more frequent reported sensations for placebo solution (S3 Fig).
Intensity of placebo-induced sensations
Susceptible subjects reported moderate to strong sensations under placebo stimulation. On a
0–100 VAS, maximum sensation intensities related to placebo irritant solution were as high as
82 / 87 / 75, for stimulation at the abdomen / finger / toe, respectively (maximum values re-
ported by any subject). For placebo laser stimulation, the values were 85 / 82 / 83, respectively.
The mean intensities (±S.D.) were 22.2 ± 17.2 / 26.6 ± 20.5 / 23.0 ± 17.8 for placebo irritant so-
lution and 35.5 ± 24.1 / 40.5 ± 24.7 / 39.2 ± 24.6 for placebo laser, for the 3 loci, respectively.
Placebo-Induced Somatic Sensations
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For all stimulation sites, placebo laser elicited significantly stronger sensations than placebo ir-
ritant solutions (abdomen: p = 0.010, finger: p = 0.0084, toe: p = 0.0018).
Geometric features of placebo-induced sensations
Sensation maps derived from subjects’ drawings in Experiments 1 and 2 showed that placebo
stimulation elicited sensations that were not confined to the point of stimulation, but were
often referred to remote body areas and even to the contralateral side of the body (Fig 2). In
some subjects, sensations from stimulation of the little toe were felt up to the thigh area, where-
as sensations from stimulation of the little finger reached to the upper arm and shoulder
region.
Sensations were significantly more widespread under placebo laser (205.1 ± 313.4 mm²)
than under placebo irritant solution (73.3 ± 178.9 mm², p = 0.010), whereas the overall length
of line-like sensations only showed a tendency (30.2 ± 29.0 mm vs. 11.4 ± 16.4 mm, p = 0.070).
Sensation maps derived from subject’s drawings in Experiment 3 revealed that the localiza-
tion of imagined sensations was remarkably similar across subjects (Fig 3). This was despite
the fact that subjects were free to choose any location on the body to draw their line. Visual in-
spection revealed that the averaged patterns were very similar for susceptible and non-suscepti-
ble subjects, although susceptible subjects seemed to show more sensation referral to proximal
areas, like the upper arm and shoulder. Interestingly, imagined sensation paths diverged at the
wrist in both groups and further followed the median and ulnar aspects of the inner forearm.
Comparison of sensation patterns with laser-evoked sensations and
referred pain
The spatial patterns of placebo-induced sensations from Experiments 2 and 3 were remarkably
similar to those of referred pain and sensations from low-level laser stimulation (Fig 4). In the
back view of the body outline, all four patterns involved some parts of the little finger, the ulnar
aspect of the forearm, the area over the triceps as well as the area of the shoulder blade. In the
front view of the body outline, sensations from placebo-laser stimulation were restricted to the
hand, while all other three patterns involved the little finger, the ulnar aspect of the forearm,
and the inner side of the upper arm.
Verbal descriptors for placebo-induced sensations
In Experiments 1 and 2, susceptible subjects chose an average (±S.D.) of 4.10 ± 2.40 different
McGill questionnaire descriptors for sensations elicited by placebo irritant solution and
4.20 ± 3.46 descriptors for those elicited by placebo laser (no significant difference, p = 0.976).
Although half of the descriptors (39 of 78) were chosen at least once in either experiment,
only nine descriptors were chosen by more than 20% of the subjects. Intensity information
(VAS scores) for these descriptors are reported in S4 Fig. In terms of absolute frequencies,
these descriptors together explained 59.9% of all choices – a value that was even larger (71.7%),
when we accounted for repeated entries by the same subjects. These descriptors were “tingling”
(70%/63.3% of subjects for irritant solution/laser), “warm” (20.0%/63.3%), “pulsing” (16.7%/
36.7%), “pressing” (26.7%/13.3%), “stinging” (13.3%/26.7%), “cold” (26.7%/10.0%), “burning”
(26.7%/10.0%), “tugging” (16.7%/23.3%), and “cool” (20.0%/10.0%) (Fig 5). The descriptor
“warm” showed the only significant difference between placebos (U = 255, z = 2.88, p = 0.004).
Subjects added a total of 13 descriptors of their own. However, only one of them (“schwer”,
English: “heavy”), was chosen by multiple subjects (1 for irritant solution, 3 for laser).
Placebo-Induced Somatic Sensations
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Fig 2. Spatial patterns of placebo-induced sensations. Sensations elicited by placebo irritant solution (left) and placebo laser (right). The stimulation site
is marked with an arrowhead. Only areas that were reported by two or more subjects are shown. Note the referral of sensations to areas remote from the
stimulation site as well as to the contralateral side of the body.
doi:10.1371/journal.pone.0124808.g002
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In Experiment 3, a total of eight descriptors were reported by susceptible subjects: “warm”
(50.0%), “tingling” (43.8%), “radiating” (37.5%), “pricking”, “numbing”, “pressing”, “as if the
limb had gone to sleep”, and “wanted to pull the limb away” (all 6.3%, i.e. once).
Comparison of the pooled data from Experiments 1 and 2 for different stimulation sites
(S5 Fig) revealed that “tingling” was the only descriptor to show significantly different frequen-
cies: It was chosen more frequently under stimulation of the finger (W = 140, ns/r = 19,
z = 2.81, p = 0.005) and toe (W = 165, ns/r = 19, z = 3.31, p = 0.0009) than for the abdomen.
Onset of placebo-induced sensations
Onsets ranged from instantaneous to 170s and showed a highly skewed distribution for both
placebos (Fig 6). The median values were 38 s for placebo irritant solution and 43 s for placebo
laser stimulation. There was no significant difference between the distributions (p = 0.464).
Influence of character traits
Subjects that were susceptible to placebo-induced sensations had significantly lower TCI scores
in novelty seeking compared to non-susceptible subjects (45.2 ± 8.5 vs. 53.4 ± 11.9, p = 0.0071,
see Fig 7) pointing to a higher basal dopaminergic activity in susceptible subjects [24]. No
other temperament of the TCI showed significant differences.
Credibility of the placebos
When asked for the purpose of the study, only a minority of subjects suspected a placebo ex-
periment (3 in Experiment 1 and 1 in Experiment 2). The other answers for Experiment 1
were: “Perception experiment” (8 subjects), “drug test” (6 subjects), “general reaction to drug /
physiological effects” (5), “pain experiment" (4), not specified (4). For Experiment 2, subjects
answered: “Test of a therapeutic device” (7 subjects), “general reaction to laser / physiological
effects” (6), “perception experiment” (6), “pain experiment” (3), not specified (7).
Discussion
In this study, we have shown that placebo-induced somatic sensations are a frequent phenome-
non that can result from a range of different placebo interventions, with or without tactile affer-
ence. While there have been reports of placebo-induced somatic sensations before [16,18,20],
this is the first paper to quantify their spatial and temporal characteristics and to compare
different placebos.
We found that sensations can reach considerable intensity and spatial extent, underlining
the clinical relevance of our findings. Specifically, similar sensations can be triggered by many
clinical interventions involving spatially localized stimulation. In our opinion, this phenome-
non deserves more research attention.
Different placebos demonstrated mostly similarities in their evoked sensations. We were
surprised by the high similarity of qualitative features as well as spatial patterns across subjects
in Experiments 1 and 2 (in Experiment 3 they were to be expected). Despite the fact that sub-
jects were not conditioned and received no explicit suggestion as to what sensations they were
about to feel, only 9 out of 78 possible McGill questionnaire descriptors were chosen by at least
Fig 3. Spatial patterns of placebo-induced sensations as imagined by subjects to result from laser stimulation. The color in each point represents the
number of subjects that imagined having sensations in that location. Only areas that were reported by two or more subjects are shown. The site of (imagined)
stimulation is marked with an arrowhead. The upper image shows the results from subjects that actually experienced sensations during imagination, the
lower of those who did not. Note the remarkable amount of overlap of sensations in both groups as well as the divergence of lines into an ulnar and a median
line at the wrist.
doi:10.1371/journal.pone.0124808.g003
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Fig 4. Similarities of placebo-induced sensations and referred pain. Spatial comparison showing similarities of placebo-induced and imagination-
induced sensation patterns (center) with patterns from low-level laser stimulation (left) and referred pain induced by hypertonic saline injection into
paravertebral muscles (right) as reported in [31].
doi:10.1371/journal.pone.0124808.g004
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20 percent of the subjects and together explained 71.7 percent of all sensation choices. More-
over, temporal onset showed a rather broad distribution that was similar for both placebo laser
and placebo irritant solution, while spatial pattern analysis revealed a high degree of overlap in
localization of sensations between the two placebo interventions. However, we also found dif-
ferences between placebos. Sensation intensity (VAS) was stronger for placebo laser stimula-
tion and sensations were more widespread (GIS). This is in line with previous reports
demonstrating stronger placebo effects from device placebos compared to other types [6,7,9].
Although somatic sensations were evoked by placebo intervention in our study, similar sen-
sations have been reported in response to low-level laser stimulation [20,22], acupuncture [32–
34], and so called touch healing [35]. In acupuncture, these sensations are part of the character-
istic “Deqi” sensation but can also be produced by placebo acupuncture [17,36]. In touch heal-
ing, evoked sensations are referred to as “enhanced touch sensations” [35]. Considering the
fact that both verum and placebo stimulation are capable of eliciting sensations that patients
frequently associate with treatment efficacy [35], one may interpret these sensations as a “pla-
cebo enhancer”, i.e. a phenomenon increasing patients’ belief that “something is happening” as
a result of the intervention, which may boost expectancy and trigger a (larger) clinical placebo
response.
Fig 5. Verbal descriptors for sensations. Incidence of the nine most common verbal descriptors for
placebo-induced sensations. Of all 78 possible descriptors, these were the only ones chosen by 20% or more
of the subjects. Together, they accounted for 59.9% of all reported sensations, which illustrates the similarity
of sensations across subjects. Results from the imagined stimulation (experiment 3) are shown in the small
box. In addition to the two most common descriptors from experiments 1 and 2, subjects frequently reported
radiating sensations for imagined stimulation.
doi:10.1371/journal.pone.0124808.g005
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Although the association between placebo-induced sensations and clinically relevant place-
bo responses have not been investigated yet, there have been reports that sensory suggestibility
affects the magnitude of the placebo effect. For instance, subjects prone to develop sensations
upon suggestion showed stronger placebo analgesic responses [37]. Furthermore, indirect sup-
port for a link between placebo-induced sensations and clinical placebo effects comes from our
observation that novelty seeking, a character trait associated with dopaminergic activity
[24,28,29], was significantly less pronounced in subjects susceptible to develop placebo-in-
duced sensations. The same character trait together with other dopamine-related traits has
been previously reported to correlate with placebo analgesia [23] and general placebo responses
[38], although the exact relationship observed in those studies was opposite to ours. In summa-
ry, a dopamine-related mechanism may underlie both, placebo-induced sensations and clinical
placebo effects.
Fig 6. Onset of sensations. Histograms of placebo-induced sensation onset time (defined as the time between the announced placebo stimulation and the
onset of the first sensation reported by the subject). Median values were 38s for placebo irritant solution and 42.5s for placebo laser. No difference between
distributions was found.
doi:10.1371/journal.pone.0124808.g006
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An interesting observation was the referral of sensations to body areas remote from the
stimulation site. This phenomenon is reminiscent of referred pain, where pain from a somatic
or visceral region is referred to remote parts of the body [25,31,39]. We found that spatial pat-
terns of placebo-induced sensations were remarkably similar to those known from experimen-
tally evoked referred pain. Although the quality of placebo-induced somatic sensations seems
to differ greatly from that of referred pain, a more careful investigation shows that the two phe-
nomena share many descriptors. While “pressing” is one of the most typical referred pain de-
scriptors [40], there is often an additional paresthetic component to it, frequently described as
“tingling” and “radiating” [41]. More support for a common mechanism between referred pain
and placebo-induced sensations comes from the average onset times. In our study, subjects re-
ported their first sensation 40.0±46.0 seconds after receiving the information that stimulation
had started. This is very similar to the typical onset of referred pain after hypertonic saline in-
jections (e.g. 42.3±32.7 seconds in[42]). Future research should directly evaluate placebo sensa-
tions and referred pain in the same individuals.
We can further speculate about underlying mechanisms of placebo sensations on the basis
of the most frequent descriptors. Of all 78 possible words from the McGill questionnaire, only
nine were chosen by more than 20% of the subjects and account for 71.7 percent of all choices.
These descriptors reflect the entire bandwidth of possible somatic sensations: “Warm”, “cool”
and “cold” express temperature sensations, while “pulsing” describes an enhanced perception
of one’s cardiac pulse. Others, like “pressing” and “tugging” are innocuous tactile sensations,
whereas “stinging” and “burning” describe nociceptive afference. The peripheral and central
processing mechanisms supporting “tingling”, which was the most frequent sensation, are not
well understood. Human microneurography experiments have shown that tingling results
Fig 7. Differences in character traits of susceptible and non-susceptible subjects.Results from a
comparison of character traits in subjects with and without placebo-induced sensation during imagined
stimulation (experiment 3). Susceptible subjects showed a significantly lower TCI score in the “novelty
seeking” category (p = 0.0071) pointing to higher basal dopaminergic activity in these subjects [24].
doi:10.1371/journal.pone.0124808.g007
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from aberrant activity of mechano-sensitive neurons [43,44]. More recent studies have applied
natural alkylamids that produce a strong tingling sensation and found that they activate a sub-
set of Aβ-, Aδ- and C-fibres that under normal circumstances convey light-touch information
from hairs in the skin [45,46]. Interestingly, tingling sensations can also arise in the complete
absence of external stimuli [47].
Due to the lack of tactile input for placebo-induced sensations, specifically for placebo laser,
our observations point towards a central rather than a peripheral etiology. The fact that placebo
sensations develop in the complete absence of tactile or thermal stimuli together with the sheer
number of differential somatosensory sub-systems involved, make involvement of peripheral
receptors and fibers unlikely. Moreover, previous studies have demonstrated that tingling sen-
sations, in particular, can be elicited by electrical stimulation of central regions, like the primary
and secondary somatosensory cortex or the somatosensory thalamus [48,49], and similar sen-
sations can arise during paresthetic epileptiform seizures [50]. Interestingly, such seizures
occur much more frequently on the extremities than on the trunk [50] which has an intriguing
parallel in our study, as tingling sensations were significantly more often reported from stimu-
lation of the finger and toe as compared to the abdomen.
More evidence for a central etiology comes from evident similarities between placebo-in-
duced sensations and those seen in some forms of synesthesia and in sensory imagery. Synes-
thesia is the involuntary experiences in one sensory pathway (“concurrent”) upon stimulation
of a different sensory pathway (“inducer”) [51,52]. As has been demonstrated by numerous
studies, somatic sensations can be induced by sound in so-called auditory-tactile synesthesia
[53], by taste in so-called taste-touch synesthesia and by the sight of other people being touched
in so-called mirror-touch synesthesia [54,55]. A common explanation for these phenomena is
cross-modal activation of adjacent (or distant but connected) brain regions that under normal
circumstances process information from each of the sensory pathways separately [56]. On the
other hand, sensory imagery has been shown by recent studies applying functional MRI to be
perceptually grounded, i.e. the cortical representation of imagined sensations overlap with
those that are actually involved in processing external sensory stimuli, like the primary somato-
sensory and insular cortices [57,58].
The conclusion of a central etiology, however does not explain, how these central sensations
are triggered. While a previous study has shown amplification of tactile sensation by placebo
[59], our results are different in that there was no external stimulus to be amplified, particularly
for placebo laser, except for possible tonic subliminal receptor activity.
However, as the recent literature on sensory processing (reviewed in [60]) shows, the central
dogma of information flow from lower to higher cortical areas is gradually being replaced by a
paradigm, in which top-down mechanisms, like expectation and prior knowledge, profoundly
shape the way that sensory input is processed. As the authors conclude, under such a view,
there is no starting point for information flow. Our results seem to support this paradigm. As
the results of Experiment 3 show, patterns of expected and perceived sensations under imag-
ined laser stimulation exhibited a high degree of similarity. Thus, subjects had similar expecta-
tions about where sensations would arise, but mainly those with low novelty seeking scores
actually developed them.
We note that our definition of the word placebomay require some clarification. While pre-
vious definitions have implicitly or explicitly assumed a clinical or therapeutic context of place-
bos (cf. Shapiro’s definition from 1968 [14]), here we have studied sham procedures similar to
those commonly used in placebo studies (lasers, topical medication) without explicitly refer-
ring to any therapeutic potential. A similar approach has recently been applied to study ampli-
fication of tactile sensation by placebo [59]. Despite the lack of a clear medical context, our
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study can nevertheless be seen as a mechanistic placebo study, informing psychophysical as-
pects of stimulation by inert substances.
We should also note several limitations. Firstly, we did not use a double-blinded design.
This means that in Experiment 1 and 2 we cannot exclude a possible influence of the experi-
menter carrying out the stimulation. Secondly, our study suffers from the limitation that it can-
not eliminate report bias, a phenomenon that is common to any placebo study examining
subjective sensations while lacking objective measures or neurobiological correlates [61].
Thirdly, the approach used to map subjects’ sensations did not differentiate between qualities.
Thus, it is possible that a subject reporting warm and tingling sensations may have felt a tin-
gling in one and warmth in another area. It may be worthwhile to use separate drawings for
each sensation, if subjects report differential spatial distributions. Fourthly, the TCI was only
used in Experiment 3, thus, limiting respective findings to the case of imagined stimulation.
Fifthly, we note that there are design differences that make Experiment 3 a suboptimal control
for Experiments 1 and 2. Experimental demand and response bias as potentially induced by the
experimenter were probably much weaker in Experiment 3 and subjects did not have an actual
placebo intervention before imagining it. Sixthly, since we have not measured participants’ ex-
pectations or prior experience with laser or irritant solution, our interpretation of mechanism
regarding expectations and/or conditioning must remain speculative. Future studies may want
to conduct the study described in our Experiment 3 in the laboratory, using the same placebo
interventions as in Experiments 1 and 2, while informing subjects that the interventions are
placebos (overt placebo design). Such an approach could help isolate the specific effect of place-
bo versus the effect of attention to the body part or sensation under study.
To conclude, the present study has shown that placebo-induced sensations are frequent and
can reach considerable intensity and extent. Their spatial pattern and sensory quality exhibit
high similarity across subjects. Interestingly, different modalities of placebo interventions pro-
duce different intensities of placebo sensations. Since a multitude of somatosensory subsystems
are involved despite the lack of a peripheral stimulus, we propose a central etiology of the phe-
nomenon. Future studies should distinguish the neural underpinnings of these sensations with
functional neuroimaging methods.
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